Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.
Sonoma BioTherapeutics continues to work toward its goal of restoring immune system balance through complementary regulatory T cell therapy and effector T cell conditioning, this time with the help of an oversubscribed Series B round.
With the acquisition of the Roche stake, SoftBank has become one of the company’s biggest stakeholders.
The company struck two separate collaborations over the past two days in order to advance the development of new, innovative medications.
Show me the money! This week’s who’s who of IPOs and financing rounds in the biopharma world.
Schrödinger and Zai Lab have announced a worldwide development and commercialization collaboration to advance a novel oncology program targeting the DNA damage repair pathway.
Ardelyx indicates the restructuring plan will save $17 million in annual cash compensation although there will be a restructuring charge of about $3.4 million.
The new $550 million site in N.C. follows the advanced packaging plant in Ohio that will significantly expand the company’s manufacturing capacity in the U.S.
Shares of Zymergen plummeted by 68% Tuesday from its April IPO price of $31 per share to just $11.7 per share after news that the company will not likely see revenue anytime soon.
Iterative Scopes closed on a $30 million Series A round. It was led by new investor Obvious Ventures, with participation from Eli Lilly, Johnson & Johnson Innovation – JJDC, Breyer Capital and Seae Ventures, in addition to Lee Shapiro, Zach Weinberg and Nat Turner.